Punchline at the end: " the Company wishes to inform shareholders that the documentation has been submitted to the U.S. Food and Drug Administration (FDA) requesting a meeting for Cellceutix's planned phase 2 trial of Kevetrin for ovarian cancer."

We'll be getting a lot more info when they get the trial design approved. We should be able to draw lots of conclusions about efficacy based on the trial design.